Effects of weight loss in obese cats on biochemical analytes related to inflammation and glucose homeostasis

Domestic Animal Endocrinology

Volumn 42, Issue 3, 2012, Pages 129-141

  Tvarijonaviciute, A ^a   Ceron, J J ^a   Holden, S L ^b   Morris, P J ^c   Biourge, V ^d   German, A J ^b  

^a UNIVERSITY OF MURCIA   (Spain)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c WALTHAM CENTRE FOR PET NUTRITION   (United Kingdom)

^d Royal Canin Research Center   (France)

Author keywords

Acute phase protein; Adipose tissue; Diabetes mellitus; Feline; Obesity

Indexed keywords

ADIPONECTIN; ARYLDIALKYLPHOSPHATASE; CHOLINESTERASE; GLUCOSE; HAPTOGLOBIN; INSULIN; SERUM AMYLOID A; SOMATOMEDIN C;

ANIMAL; ARTICLE; BLOOD; CAT; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; INFLAMMATION; MALE; METABOLISM; OBESITY; PHYSIOLOGY; WEIGHT REDUCTION;

ADIPONECTIN; ADIPOSITY; ANIMALS; ARYLDIALKYLPHOSPHATASE; BLOOD GLUCOSE; BUTYRYLCHOLINESTERASE; CATS; FEMALE; GLUCOSE; HAPTOGLOBINS; HOMEOSTASIS; INFLAMMATION; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MALE; OBESITY; SERUM AMYLOID A PROTEIN; WEIGHT LOSS;

FELIDAE;

EID: 84858076251     PISSN: 07397240     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.domaniend.2011.10.003     Document Type: Article

References (51)

1. Lund E.M., Armstrong P.J., Kirk C.A., Klausner J.S. Prevalence and risk factors for obesity in adult cats from private US veterinary practices. Intern J Appl Res Vet Med 2005, 3:88-96.
2. German A.J. The growing problem of obesity in dogs and cats. J Nutr 2006, 136:1940S-1946S.
3. Trayhurn P. Adipose tissue in obesity-an inflammatory issue. Endocrinologist 2005, 146:1003-1005.
4. Esposito K., Pontillo A., Di Palo C., Giugliano G., Masella M., Marfella R., Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289:1799-1804.
5. German A.J., Holden S.L., Bissot T., Morris P.J., Biourge V. Changes in body composition during weight loss in obese client-owned cats: loss of lean tissue mass correlates with overall percentage of weight lost. J Fel Med Surg 2008, 10:452-459.
6. Tvarijonaviciute A., Martinez S., Gutierrez A., Ceron J.J., Tecles F. Serum acute phase proteins concentrations in dogs during experimentally short-term induced overweight. A preliminary study. Res Vet Sci 2011, 90:31-34.
7. Randell E.W., Mathews M.S., Zhang H., Seraj J.S., Sun G. Relationship between serum butyrylcholinesterase and the metabolic syndrome. Clin Biochem 2005, 38:799-805.
8. Tvarijonaviciute A., Tecles F., Ceron J.J. Relationship between serum butyrylcholinesterase and obesity in dogs: A preliminary report. Vet J 2010, 186:197-200.
9. Noncholinergic Function of Cholinesterase in Enzymes in the Cholinergic Family 1995, Plenum, New York, 426-426. K.M. Kutty, V. Prabhakaran, A.R. Cooper, D. Quin (Eds.).
10. Jain R., Kutty K.M., Huang S.N., Kean K. Pseudocholinesterase/high-density lipoprotein cholesterol ratio in serum of normal persons and of hyperlipoproteinemics. Clin Chem 1983, 29:1031-1033.
11. Magarian E.O., Dietz A.J. Correlation of cholinesterase with serum lipids and lipoproteins. J Clin Pharmacol 1987, 27:819-820.
12. Bergmeier C., Siekmeier R., Gross W. Distribution spectrum of paraoxonase activity in HDL fractions. Clin Chem 2004, 50:2309-2315.
13. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991, 286:152-154.
14. Dullaart R.P., Vries R., Sluiter W.J., Voorbij H.A. High plasma C-reactive protein is related to low paraoxonase-I activity independently of high leptin and low adiponectin in type 2 diabetes mellitus. Clin Endocrinol 2009, 70:221-226.
15. Kotani K., Sakane N., Sano Y., Tsuzaki K., Matsuoka Y., Egawa K., Yoshimura M., Horikawa C., Kitagawa Y., Kiso Y., Kimura S., Schulze J., Taing J., Gugliucci A. Changes on the physiological lactonase activity of serum Paraoxonase 1 by a diet intervention for weight loss in healthy overweight and obese women. J Clin Biochem Nutr 2009, 45:329-334.
16. Tanner A.E., Martin J., Saker K.E. Oxidative stress and inflammatory state induced by obesity in the healthy feline. J Anim Physiol Anim Nutr 2007, 91:163-165.
17. Chandran M., Ciaraldi T., Phillips S.A., Henry R.R. Adiponectin: more than just another fat cell hormone?. Diabetes Care 2003, 26:2442-2450.
18. Ishioka K., Omachi A., Sasaki N., Kimura K., Saito M. Feline adiponectin: molecular structures and plasma concentrations in obese cats. J Vet Med Sci 2009, 71:189-194.
19. Tvarijonaviciute A., Eralp O., Kocaturk M., Yilmaz Z., Ceron J.J. Adiponectin and IGF-1 are negative acute phase proteins in a dog model of acute endotoxaemia. Vet Immunol Immunopathol 2011, 140:147-151.
20. Rasmussen M.H., Frystyk J., Andersen T., Breum L., Christiansen J.S., Hilsted J. The impact of obesity, fat distribution, and energy restriction on insulin-like growth factor-1 (IGF-1), IGF-binding protein-3, insulin, and growth hormone. Metabolism 1994, 43:315-319.
21. Janssen J.A., Lamberts S.W. The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible?. Eur J Endocrinol 2002, 146:467-477.
22. Reusch C.E., Kley S., Casella M., Nelson R.W., Mol J., Zapf J. Measurements of growth hormone and insulin-like growth factor 1 in cats with diabetes mellitus. Vet Rec 2006, 158:195-200.
23. Smith W.J., Underwood L.E., Clemmons D.R. Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults. J Clin Endocrinol Metab 1995, 80:443-449.
24. Laflamme D.P. Development and validation of a body condition score for cats: a clinical tool. Feline Pract 1997, 25:13-18.
25. Raffan E., Holden S.L., Cullingham F., Hackett R.M., Rawlings J.M., German A.J. Standardized positioning is essential for precise determination of body composition using dual-energy x-ray absorptiometry in dogs. J Nutr 2006, 136:1976S-1978S.
26. Abbot Animal Health. Glucose Monitoring, Accessed March 3, 2011. http://www.abbottanimalhealth.com/veterinary-professionals/products/glucose-monitoring.html.
27. Appleton D.J., Rand J.S., Sunvold G.D. Basal plasma insulin and homeostasis model assessment (HOMA) are indicators of insulin sensitivity in cats. J Fel Med Surg 2005, 7:183-193.
28. Tvarijonaviciute A., German A.J., Martínez-Subiela S., Tecles F., Ceron J.J. Analytical performance of commercially available assays for feline IGF-1, adiponectin, and ghrelin measurements. J Fel Med Surg 2012, 14(2):138-146.
29. Hansen A.E., Schaap M.K., Kjelgaard-Hansen M. Evaluation of a commercially available human serum amyloid A (SAA) turbidimetric immunoassay for determination of feline SAA concentration. Vet Res Commun 2006, 30:863-872.
30. Tecles F., Martinez-Subiela S., Bernal L.J., Cerón J.J. Use of whole blood for spectrophotometric determination of cholinesterase activity in dogs. Vet J 2000, 160:242-249.
31. Haagen L., Brock A. A new automated method for phenotypingarylesterase (EC C.3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992, 30:391-395.
32. Browne R.W., Koury S.T., Marion S., Wilding G., Muti P., Trevisan M. Accuracy and biological variation of human serum paraoxonase 1 activity and polymorphism (Q192R) by kinetic enzyme assay. Clin Chem 2007, 53:310-317.
33. Hoenig M., Jordan E.T., Ferguson D.C., de Vries F. Oral glucose leads to a differential response in glucose, insulin, and GLP-1 in lean versus obese cats. Domest Anim Endocrinol 2010, 38:95-102.
34. Ceron J.J., Eckersall P.D., Martinez-Subiella M. Acute phase proteins in dogs and cats: current knowledge and future perspectives. Vet Clin Pathol 2005, 34:85-89.
35. Selvin E., Paynter N.P., Erlinger T.P. The effect of weight loss on C-reactive protein: a systematic review. Arch Intern Med 2007, 167:31-39.
36. German A.J., Ryan V.H., German A.C., Wood I.S., Trayhurn P. Obesity, its associated disorders and the role of inflammatory adipokines in companion animals. Vet J 2010, 185:4-9.
37. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., Rifai N., Smith S.C., Taubert K., Tracy R.P., Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511. Centers for Disease Control and Prevention, American Heart Association.
38. Pardina E., Ferrer R., Baena-Fustegueras J.A., Lecube A., Fort J.M., Vargas V., Catalán R., Peinado-Onsurbe J. The relationships between IGF-1 and CRP, NO, leptin, and adiponectin during weight loss in the morbidly obese. Obes Surg 2010, 20:623-632.
39. Frystyk J., Vestbo E., Skjaerbaek C., Mogensen C.E., Orskov H. Free insulin-like growth factors in human obesity. Metabolism 1995, 44:37-44.
40. Ekman B., Nyström F., Arnqvist H.J. Circulating IGF-I concentrations are low and not correlated to glycaemic control in adults with type 1 diabetes. Eur J Endocrinol 2000, 143:505-510.
41. Hotta K., Funahashi T., Bodkin N.L., Ortmeyer H.K., Arita Y., Hansen B.C., Matsuzawa Y. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001, 50:1126-1133.
42. Iwabu M., Yamauchi T., Okada-Iwabu M., Sato K., Nakagawa T., Funata M., Yamaguchi M., Namiki S., Nakayama R., Tabata M., Ogata H., Kubota N., Takamoto I., Hayashi Y.K., Yamauchi N., Waki H., Fukayama M., Nishino I., Tokuyama K., Ueki K., Oike Y., Ishii S., Hirose K., Shimizu T., Touhara K., Kadowaki T. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature 2010, 464:1313-1319.
43. Matsuzawa Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl 2005, 6:7-14.
44. Faraj M., Havel P.J., Phélis S., Blank D., Sniderman A.D., Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003, 88:1594-1602.
45. Veiga L., Silva-Nunes J., Melão A., Oliveira A., Duarte L., Brito M. Q192R polymorphism of the Paraoxonase-1 gene as a risk factor for obesity in Portuguese women. Eur J Endocrinol 2011, 164:213-218.
46. Zhou Q., Du J., Zhaoyong H., Walsh K., Wang X.H. Evidence for adipose-muscle cross talk: opposing regulation of muscle proteolysis by adiponectin and fatty acids. Endocrinologist 2007, 148:5696-5705.
47. Wang X., Hu Z., Hu J., Du J., Mitch W.E. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinologist 2006, 147:4160-4168.
48. Alves-Amaral G., Pires-Oliveira M., Andrade-Lopes A.L., Chiavegatti T., Godinho R.O. Gender-related differences in circadian rhythm of rat plasma acetyl- and butyrylcholinesterase: effects of sex hormone withdrawal. Chem Biol Interact 2010, 186:9-15.
49. Juul A., Bang P., Hertel N.T., Main K., Dalgaard P., Jørgensen K., Müller J., Hall K., Skakkebaek N.E. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994, 78:744-752.
50. Bergman R.N., Ider Y.Z., Bowden C.R., Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol 1979, 236:E667-E677.
51. Metabolizable energy protocol and affidavits 2010, 169-183. Association of American Feed Control Officials, AAFCO, Washington DC.